ZA201001935B - Process for the preparation of a raf kinase inhibitor and intermediates for use in the process - Google Patents

Process for the preparation of a raf kinase inhibitor and intermediates for use in the process

Info

Publication number
ZA201001935B
ZA201001935B ZA2010/01935A ZA201001935A ZA201001935B ZA 201001935 B ZA201001935 B ZA 201001935B ZA 2010/01935 A ZA2010/01935 A ZA 2010/01935A ZA 201001935 A ZA201001935 A ZA 201001935A ZA 201001935 B ZA201001935 B ZA 201001935B
Authority
ZA
South Africa
Prior art keywords
intermediates
preparation
kinase inhibitor
raf kinase
raf
Prior art date
Application number
ZA2010/01935A
Other languages
English (en)
Inventor
Maruti Ghagare
Sandip Chikhalikar
Rajendra Narayanrao Kankan
Dharmaraj Ramachandra Rao
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of ZA201001935B publication Critical patent/ZA201001935B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/58—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/15—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/64—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups singly-bound to oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2010/01935A 2007-09-10 2010-03-18 Process for the preparation of a raf kinase inhibitor and intermediates for use in the process ZA201001935B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1734MU2007 2007-09-10
IN1733MU2007 2007-09-10
PCT/GB2008/003048 WO2009034308A2 (en) 2007-09-10 2008-09-10 Process for the preparation of a raf kinase inhibitor and intermediates for use in the process

Publications (1)

Publication Number Publication Date
ZA201001935B true ZA201001935B (en) 2010-11-24

Family

ID=40351766

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/01935A ZA201001935B (en) 2007-09-10 2010-03-18 Process for the preparation of a raf kinase inhibitor and intermediates for use in the process

Country Status (9)

Country Link
US (1) US8445687B2 (enExample)
EP (1) EP2195286A2 (enExample)
JP (1) JP5438680B2 (enExample)
KR (1) KR101553211B1 (enExample)
AU (1) AU2008299703C1 (enExample)
CA (1) CA2698795C (enExample)
NZ (1) NZ583790A (enExample)
WO (1) WO2009034308A2 (enExample)
ZA (1) ZA201001935B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Corporation .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2324825A1 (en) 2002-02-11 2011-05-25 Bayer Healthcare LLC Aryl ureas with angiogenesis inhibiting activity
ES2288694T3 (es) 2003-05-20 2008-01-16 Bayer Pharmaceuticals Corporation Diaril ureas para enfermedades mediadas por el receptor del factor de crecimiento derivado de plaquetas.
KR101553211B1 (ko) 2007-09-10 2015-09-15 씨아이피엘에이 엘티디. Ｒａｆ 키나아제 저해제의 제조방법 및 상기 제조방법에 사용되는 중간체
AU2009289319C1 (en) 2008-09-02 2013-12-05 Novartis Ag Picolinamide derivatives as kinase inhibitors
AU2010299483B2 (en) 2009-09-24 2014-08-28 Sun Pharmaceutical Industries Limited Process for the preparation of sorafenib tosylate
US8604208B2 (en) 2009-09-24 2013-12-10 Ranbaxy Laboratories Limited Polymorphs of sorafenib acid addition salts
US8552197B2 (en) 2009-11-12 2013-10-08 Ranbaxy Laboratories Limited Sorafenib ethylsulfonate salt, process for preparation and use
AU2011210326B2 (en) 2010-01-29 2014-10-09 Sun Pharmaceutical Industries Limited Sorafenib dimethyl sulphoxide solvate
CN102190616B (zh) * 2010-03-18 2015-07-29 苏州泽璟生物制药有限公司 一种氘代的ω-二苯基脲的合成及生产的方法和工艺
SG191309A1 (en) * 2011-01-18 2013-07-31 Glaxo Group Ltd Process for the preparation of retigabine
CN102485714B (zh) * 2011-10-09 2013-07-24 连云港盛和生物科技有限公司 一种羰基化合成索拉菲尼的方法
AP2014008046A0 (en) 2012-05-21 2014-11-30 Novartis Ag Novel ring-substituted N-pyridinyl amides as kinase inhibitors
CN103508961B (zh) 2012-06-26 2015-07-22 中美冠科生物技术（太仓）有限公司 抗肿瘤药物
CN103408488A (zh) * 2013-08-13 2013-11-27 张家港威胜生物医药有限公司 一种索拉非尼的优化合成方法
JP6612232B2 (ja) 2013-08-28 2019-11-27 クラウン バイオサイエンス インコーポレイテッド（タイカン） 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用
CN104761492A (zh) * 2014-01-03 2015-07-08 正大天晴药业集团股份有限公司 对甲苯磺酸索拉非尼的晶型及其制备方法
CN105481764A (zh) * 2014-09-16 2016-04-13 重庆圣华曦药业股份有限公司 一种索拉非尼对甲苯磺酸盐的制备方法
CN105399668B (zh) * 2015-12-29 2018-11-16 开封制药(集团)有限公司 一种“一锅法”制备索拉菲尼的方法
CN105801475B (zh) * 2016-04-25 2018-01-12 华润双鹤利民药业（济南）有限公司 一种甲苯磺酸索拉非尼的制备方法
CN109796400B (zh) * 2017-11-16 2022-07-29 四川科伦药物研究院有限公司 一种甲苯磺酸索拉菲尼晶型及其制备方法
CN108623521B (zh) * 2018-03-22 2020-09-04 盐城师范学院 一种乐伐替尼的制备方法
CN108586329A (zh) * 2018-03-31 2018-09-28 山东罗欣药业集团恒欣药业有限公司 一种索拉非尼的合成方法
CN108440403A (zh) * 2018-03-31 2018-08-24 山东罗欣药业集团恒欣药业有限公司 一种瑞戈非尼的制备方法
CN108341770A (zh) * 2018-03-31 2018-07-31 山东罗欣药业集团恒欣药业有限公司 一种索拉非尼化合物的制备方法
CN108276327A (zh) * 2018-03-31 2018-07-13 山东罗欣药业集团恒欣药业有限公司 一种索拉非尼的制备方法
CN108276328A (zh) * 2018-03-31 2018-07-13 山东罗欣药业集团恒欣药业有限公司 一种索拉非尼的制备方法
CN108558747A (zh) * 2018-03-31 2018-09-21 山东罗欣药业集团恒欣药业有限公司 一种瑞戈非尼的制备方法
CN108586330A (zh) * 2018-04-18 2018-09-28 日照市普达医药科技有限公司 一种治疗肿瘤药物的制备方法及其应用
WO2021013712A1 (en) 2019-07-19 2021-01-28 Anagenesis Biotechnologies S.A.S. Polyaromatic urea derivatives and their use in the treatment of muscle diseases
EP4029501A1 (en) 2021-01-19 2022-07-20 Anagenesis Biotechnologies Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL123536C (enExample) * 1963-07-09
FR1484461A (fr) * 1965-06-25 1967-06-09 Grace W R & Co Compositions herbicides
CH497117A (de) * 1968-01-12 1970-06-30 Ciba Geigy Verwendung eines Carbanilsäurederivates zum antimikrobiellen Ausrüsten bzw. zum Schützen von Textilfasern gegen Befall und Schädigung durch Mikroorganismen
CH490005A (de) * 1968-02-06 1970-05-15 Ciba Geigy Schädlingsbekämpfungsmittel
BE788983A (fr) * 1971-09-22 1973-01-15 Rolland Sa A 3-trifluoromethylanilides
US5541224A (en) * 1994-03-14 1996-07-30 Eli Lilly And Company Carbanilide anticoccidials
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
SV2001000004A (es) * 1999-01-13 2001-01-10 Bayer Corp Difenil ureas w-carboxyaril sustituidas, composición farmacéutica que las comprende y su uso como inhibidores de raf quinasa
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Corporation .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US6242385B1 (en) * 2000-02-28 2001-06-05 Uniroyal Chemical Company, Inc. Enhancement of seed/fruit/nut yields from flowering plants
WO2005021534A1 (ja) * 2003-08-28 2005-03-10 Taisho Pharmaceutical Co., Ltd. １，３−ジヒドロ−２ｈ−インドール−２−オン誘導体
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
WO2006034796A1 (en) 2004-09-29 2006-04-06 Bayer Healthcare Ag Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide
TW200730503A (en) * 2005-10-21 2007-08-16 Daiichi Seiyaku Co Tricyclic compound
WO2007064931A2 (en) * 2005-12-02 2007-06-07 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
KR101553211B1 (ko) 2007-09-10 2015-09-15 씨아이피엘에이 엘티디. Ｒａｆ 키나아제 저해제의 제조방법 및 상기 제조방법에 사용되는 중간체

Also Published As

Publication number Publication date
US20100311980A1 (en) 2010-12-09
AU2008299703A1 (en) 2009-03-19
AU2008299703C1 (en) 2013-09-05
EP2195286A2 (en) 2010-06-16
CA2698795A1 (en) 2009-03-19
WO2009034308A3 (en) 2009-07-16
WO2009034308A2 (en) 2009-03-19
CA2698795C (en) 2016-04-19
AU2008299703B2 (en) 2013-06-20
JP2010539076A (ja) 2010-12-16
NZ583790A (en) 2012-04-27
KR20100074175A (ko) 2010-07-01
JP5438680B2 (ja) 2014-03-12
US8445687B2 (en) 2013-05-21
KR101553211B1 (ko) 2015-09-15

Similar Documents

Publication Publication Date Title
ZA201001935B (en) Process for the preparation of a raf kinase inhibitor and intermediates for use in the process
IL284889A (en) Imidazotriazines and imidazopyrimidines as kinase inhibitors
AP2010005167A0 (en) Pyrazole compounds and their use as RAF inhibitors
ZA201101586B (en) Aminotriazolopyridines and their use as kinase inhibitors
IL216511A0 (en) Janus kinase inhibitor compounds and methods
IL207843A0 (en) Raf inhibitor compounds and methods of use thereof
ZA201004055B (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
IL205977A0 (en) 5-anilinoimidazopyridines and methods of use
IL219646A0 (en) Novelnaphthyridine derivatives and the use thereof as kinase inhibitors
IL196956A0 (en) Aza-benzofuranyl compounds and methods of use
EP2021555A4 (en) STRUCTURAL ELEMENT AND METHODS OF USE THEREOF
EP2023718A4 (en) CREATINLIGATE COMPOUNDS AND APPLICATION METHOD THEREFOR
IL244161A0 (en) Synchronized water, its production and use
IL193693A0 (en) Purine compounds and methods of use thereof
IL206125A0 (en) Azaindolizines and methods of use
ZA200808017B (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
TWI347620B (en) Transformer structure and manufacturing method of the same
IL200441A0 (en) Solid forms of a raf kinase inhibitor
ZA201000802B (en) Process for the preparation of alfuzosin hydrochloride
ZA200807956B (en) Purine compounds and methods of use thereof
HUP0600122A3 (en) New compounds and their use
HU0600653D0 (en) Process for producing siderofor and siderofor-laden meat-product and use thereof